Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Spyre Therapeutics (SYRE) over the last 9 years, with Q4 2024 value amounting to $115398.0.

  • Spyre Therapeutics' Treasury Shares fell 2500.05% to $115398.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $115398.0, marking a year-over-year decrease of 2500.05%. This contributed to the annual value of $115398.0 for FY2024, which is 2500.05% down from last year.
  • Per Spyre Therapeutics' latest filing, its Treasury Shares stood at $115398.0 for Q4 2024, which was down 2500.05% from $153865.0 recorded in Q4 2023.
  • In the past 5 years, Spyre Therapeutics' Treasury Shares ranged from a high of $228200.0 in Q4 2020 and a low of $5660.0 during Q4 2022
  • Moreover, its 5-year median value for Treasury Shares was $167682.5 (2022), whereas its average is $151827.9.
  • As far as peak fluctuations go, Spyre Therapeutics' Treasury Shares crashed by 9702.11% in 2022, and later soared by 261846.29% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Treasury Shares (Quarter) stood at $228200.0 in 2020, then dropped by 16.74% to $190000.0 in 2021, then crashed by 97.02% to $5660.0 in 2022, then skyrocketed by 2618.46% to $153865.0 in 2023, then dropped by 25.0% to $115398.0 in 2024.
  • Its Treasury Shares was $115398.0 in Q4 2024, compared to $153865.0 in Q4 2023 and $5660.0 in Q4 2022.